The kynurenine pathway activities in a sub-Saharan HIV/AIDS population

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Bipath, Priyesh ^a   Levay, Peter F ^b   Viljoen, Margaretha ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; KYNURENINE; NEOPTERIN; NICOTINAMIDE; PHOSPHORIBOSYLTRANSFERASE; QUINOLINATE PHOSPHORIBOSYLTRANSFERASE; QUINOLINIC ACID; TRYPTOPHAN; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLTRANSFERASE; IL6 PROTEIN, HUMAN; NICOTINATE-NUCLEOTIDE DIPHOSPHORYLASE (CARBOXYLATING);

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA SOUTH OF THE SAHARA; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEVELOPED COUNTRY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GAS CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; VITAMIN METABOLISM; ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; HIV INFECTIONS; IMMUNOLOGY; MASS FRAGMENTOGRAPHY; METABOLISM; MIDDLE AGED; POVERTY; SOUTH AFRICA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HIV INFECTIONS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; KYNURENINE; MALE; MIDDLE AGED; NEOPTERIN; NIACINAMIDE; PENTOSYLTRANSFERASES; POVERTY; QUINOLINIC ACID; SOUTH AFRICA; TRYPTOPHAN;

EID: 84939475487     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1087-5     Document Type: Article

References (56)

1. Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak, Dougherty DM. L-tryptophan: basic metabolic functions, behavioural research and therapeutic indications. Int J Tryptophan Res. 2009;2:45-60.
2. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and health states. Int J Tryptophan Res. 2009;2:1-19.
3. Samikkannu T, Saiyed ZM, Rao KVK, Babu DK, Rodriguez JW, Papuashvili MN, et al. Differential regulation of Indoleamine-2,3-dioxygenase (IDO) by HIV Type 1 Clade B and C Tat protein. AIDS Res Hum Retroviruses. 2009;25(3):329-35.
4. Boasso A, Shearer G. How does indoleamine 2,3 dioxygenase contribute to HIV-mediated immune dysregulation. Curr Drug Metab. 2007;8:217-23.
5. Murray MF. Insights into therapy: tryptophan oxidation and HIV infection. Sci Transl Med. 2010;2(32):s23.
6. Fukuwatari T, Shibata K. Nutritional aspect of tryptophan metabolism. Int J Tryptophan Res. 2013;6:3-8.
7. Murray MF. Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect Dis. 2003;3:644-52.
8. Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS: regulation by inflammatory cytokines. Front Neurosci. 2014;8(12):1-22.
9. Moffet JR, Namboodiri MA. Tryptophan and the immune response. Immunology Cell Biol. 2003;81:247-65.
10. Werner ER, Fuchs D, Hausen A, Jaeger H, Reibnegger G, Werner-Falmayer G, et al. Tryptophan degradation in patients infected by human immunodeficiency virus. Biol Chem Hoppe Seyler. 1998;369:337-40.
11. Fuchs D, Moller AA, Reibnegger G, Werner ER, Werner-Felmayer G, Dierich MP, et al. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett. 1991;28:207-11.
12. Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M. Serum kynurenine-to- tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem. 1998;44:858-62.
13. Look MP, Altfeld M, Kreuzer KA, Riezler R, Stabler SP, Allen RH, et al. Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease. AIDS Res Hum Retroviruses. 2000;16:1215-21.
14. Zangerle R, Widner B, Quirchmair G, Neurater G, Sarcletti M, Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol. 2002;104:242-7.
15. Schroeksnadel K, Sarcletti M, Winkler C, Mumelter B, Weiss G, Fuchs D, et al. Quality of life and immune activation in patients with HIV infection. Brain Behav Immun. 2008;22:881-9.
16. Hortin GL, Landt M, Powderly WG. Changes in plasma amino acid concentrations in response to HIV-1 infection. Clin Chem. 1994;40:785-9.
17. Gisslen M, Larsson M, Norkrans G, Fuchs D, Wachter H, Hagberg L. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retroviruses. 1994;10:947-51.
18. Meerman J, Carisma B, Thompson B. Global, regional and subregional trends in undernourishment and malnutrition. SOFA FOA. 2012;1:1-33.
19. Enwonwu CO. Complex interactions between malnutrition, Infection and immunity: relevance to HIV/AIDS infection. Nigerian J Clin Biomed Res. 2006;1:6-14.
20. Byakwaga H, Boum Y, Huang Y, Muzoora C, Kembabazi A, Weiser SD, et al. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014;210(3):383-91.
21. Martinez P, Tsai AC, Muzoora C, Kemabazi A, Weiser SD, Huang Y, et al. Reversal of the kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. J Acquir Immune Defic Syndr. 2014;65(4):456-62.
22. Bipath P, Viljoen M, Levay PF. Levels of procalcitonin, C-reactive protein and neopterin in patients with advanced HIV-1 infection. S Afr J HIV Med. 2012;13:78-82.
23. Li T, Iwaki H, Fu R, Hasegawa Y, Zhang H, Liu A. aα-amino-ß-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) is a new member of the amidohydrolase superfamily. Biochem. 2006;45:6628-34.
24. Fukuoka S, Ishiguro K, Yanagihara, Tanabe A, Egashira Y, Sanada H, et al. Identification and expression of cDNA encoding human aα-amino-ß-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD). J Biol Chem. 2002;277(38):35162-7.
25. Shibata K. Nutritional factors that regulate on the conversion of L-tryptophan to niacin. Adv Exp Med Biol. 1999;467:711-6.
26. Shibata K, Fukuwatari T, Sasaki R. Phthalate esters enhance quinolinate production by inhibiting amino-carboxymuconate-semialdehyde decarboxylase (ACMSD), a key enzyme of the tryptophan-niacin pathway. Int Congress Series. 2007;1304:184-94.
27. Hernandez-Diaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect. 2009;117(2):185-9.
28. Halperin JJ, Heyes MP. Neuroactive kynurenines in Lyme borrrliosis. Neurol. 1992;42:43-50.
29. Heyes MP, Saito K, Lackner A, Wiley CA, Achim CL, Markey SP. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J. 1998;12:881-96.
30. Heyes MP, Rubinow D, Lane C, Markey SP. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Ann Neurol. 1989;26(2):275-7.
31. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356-65.
32. Perez-De La Cruz V, Carrillo-Mora P, Santamaria A. Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res. 2012;5:1-8.
33. Lim CK, Yap MCC, Kent SJ, Gras G, Samah B, Batten JC, et al. Characterization of the kynurenine pathway and quinolinic acid production in macaque macrophages. Int J Tryptophan Res. 2013;6:7-19.
34. Martin A, Heyes MP, Salazar AM, Kampen DL, Williams J, Law WA, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. J Neuropsychiatry Clin Neurosci. 1992;4:270-9.
35. Brouwers P, Heyes MP, Moss HA, Wolters PL, Poplack DG, Markey SP, et al. Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: Relationship to clinical status and therapeutic response. J Infect Dis. 1993;168(6):1380-6.
36. Valle M, Price RW, Nilsson A, Heyes MP, Verotta D. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain. 2004;127:1047-60.
37. Gendelman HE, Zheng J, Coulter CL, Ghorpade A, Che M, Thylin M, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis. 1998;178:1000-7.
38. Murray MF, Nicotinamide. An oral antimicrobial agent with activity against both mycobacterium tuberculosis and human immunodeficiency virus. Clin Infect Dis. 2003;36:453-60.
39. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115-30.
40. Murray MF, Langan M, MacGregor RR. Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. Nutrition. 2001;17:654-6.
41. Monteiro JP, da Cunha DF, Filho DC, Silva-Vergara ML, dos Santos VM, da Costa JC, et al. Niacin metabolite excretion alcoholic pellagra and AIDS patients with and without diarrhea. Nutrition. 2004;20:778-82.
42. Taylor EW. The oxidative stress-induced niacin sink (OSINS) model for HIV pathogenesis. Toxicology. 2010;278(1):124-30.
43. Pitche P, Kombate K, Tchangai-Walla K. Prevalence of HIV infection in patients with pellagra and pellagra-like erythemas. Med Trop (Mars). 1999;59(4):365-7.
44. Skurnick JH, Bogden JD, Baker H, Kemp FW, Sheffet A, Quattrone G, et al. Micronutrient profiles in HIV-1 infected heterosexual adults. J AIDS Hum Retroviruses. 1996;12:75-83.
45. Bogden JD, Baker H, Frank O, Perez G, Kemp F, Breuning K, et al. Micronutrient status and human immunodeficiency virus (HIV) infection. Ann N Y Acad Sci. 1990;589:189-95.
46. Seal AJ, Creeke PI, Dibari F, Cheung F, Kyroussis E, Semedo P, et al. Low and deficient niacin status and pellagra are endemic in postwar Angola. Am J Clin Nutr. 2007;85:218-24.
47. Badawy AA. Pellagra and alcoholism: a biochemical perspective. Alcohol. 2014;49(3):238-50.
48. Mayo Clinic. Niacin (Vitamin B3, nicotinic acid), niacinamide - drugs and supplements. [ http://www.mayoclinic.org/drugs-supplements/niacin--niacinamide/dosing/hrb-20059838 ].
49. Earthman CP. Evaluation of nutrition assessment parameters in the presence of human immunodeficiency virus infection. Nutr Clin Pract. 2004;19:330-9.
50. Murray MF, Nghiem M, Srinivasan A. HIV infection decreases intracellular nicotinamide adenine dinucleotide [NAD]. Biochem Biophys Res Commun. 1995;212:126-31.
51. Foster AC, Whetsell Jr WO, Bird ED, Schwarcz R. Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington's disease and in quinolinate-lesioned rat striatum. Brain Res. 1985;336(2):207-14.
52. Braidy N, Guillemin GJ, Grant R. Effects of kynurenine pathway inhibition on NAD+ metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res. 2011;4:29-37.
53. Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 Infection. Clin Infect Dis. 2005;40:853-8.
54. Hanna LE, Nayak K, Subramanyam S, Venkatesan P, Narayanan PR, Swaminathan S. Incomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis. Indian J Med Res. 2009;129:548-54.
55. Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D. Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV1 infection and correlate with immune activation markers. Pharmacol Res. 2009;60:508-14.
56. Bogner JR, Matuschke A, Heinrich B, Eberle E, Goebel FD. Serum neopterin levels as predictor of AIDS. Klin Wochenschr. 1998;66:1015-8.